{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T23:31:18Z","timestamp":1776382278627,"version":"3.51.2"},"reference-count":29,"publisher":"American Association for Cancer Research (AACR)","issue":"19","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Purpose: The purpose of this research was to assess the feasibility of administering Col-3, an oral chemically modified tetracycline derivative with potent inhibitory effects on matrix metalloproteinase activity and production, and recommend a dose on an uninterrupted once-daily schedule. The study also sought to characterize the pharmacokinetic behavior of Col-3 and seek evidence of anticancer activity.<\/jats:p>\n               <jats:p>Experimental Design: Patients with advanced solid malignancies were treated with escalating doses of Col-3 with dose level assignment according to an accelerated titration scheme. Because photosensitivity skin reactions were being reported in concurrent trials of Col-3, patients were instructed to apply sunscreen rigorously throughout the trial. The maximum tolerated dose was defined as the highest dose at which &amp;lt;2 of the first 6 new patients experienced dose-limiting toxicity. The pharmacokinetic behavior of Col-3 was characterized, and pharmacodynamic relationships were sought.<\/jats:p>\n               <jats:p>Results: Thirty-three patients were treated with 73 courses of Col-3 at four dose levels ranging from 36 to 98 mg\/m2\/day. Unacceptably high incidences of photosensitivity skin reactions and malaise were noted in the first 28-day courses of patients treated with Col-3 at doses exceeding 50 mg\/m2\/day. At 50 mg\/m2\/day, severe toxicity occurred in 2 of 12 new patients in first courses, and no additional dose-limiting toxicities were observed in subsequent courses. Other mild to modest adverse effects included nausea, vomiting, liver function tests abnormalities, diarrhea, mucositis, leukopenia, and thrombocytopenia. The pharmacokinetics of Col-3 were dose proportional, and mean trough concentrations at steady state were similar to biologically relevant concentrations in preclinical studies. Major responses did not occur, but durable disease stability was noted in 3 patients, one each with carcinosarcoma of the uterus, pancreas, and ovary, all of whom had experienced disease progression before Col-3 treatment.<\/jats:p>\n               <jats:p>Conclusions: The recommended dose for Phase II studies of Col-3 administered once daily on an uninterrupted schedule is 50 mg\/m2\/day accompanied by efforts that promote adherence to the use of sunscreen and other photoprotective measures. Pharmacokinetic results indicate that plasma concentrations above biologically relevant concentrations are readily maintained at this dose, and additional disease-directed studies, particularly in patients with soft tissue sarcoma, should be considered.<\/jats:p>","DOI":"10.1158\/1078-0432.ccr-04-0804","type":"journal-article","created":{"date-parts":[[2005,9,21]],"date-time":"2005-09-21T23:59:27Z","timestamp":1127347167000},"page":"6512-6521","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["A Phase I and Pharmacokinetic Study of Col-3 (Metastat), an Oral Tetracycline Derivative with Potent Matrix Metalloproteinase and Antitumor Properties"],"prefix":"10.1158","volume":"10","author":[{"given":"Samira","family":"Syed","sequence":"first","affiliation":[{"name":"1Institute for Drug Development, Cancer Therapy and Research Center and University Health Science Center at San Antonio, San Antonio, Texas; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Takimoto","sequence":"additional","affiliation":[{"name":"1Institute for Drug Development, Cancer Therapy and Research Center and University Health Science Center at San Antonio, San Antonio, Texas; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Hidalgo","sequence":"additional","affiliation":[{"name":"1Institute for Drug Development, Cancer Therapy and Research Center and University Health Science Center at San Antonio, San Antonio, Texas; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinee","family":"Rizzo","sequence":"additional","affiliation":[{"name":"1Institute for Drug Development, Cancer Therapy and Research Center and University Health Science Center at San Antonio, San Antonio, Texas; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John G.","family":"Kuhn","sequence":"additional","affiliation":[{"name":"1Institute for Drug Development, Cancer Therapy and Research Center and University Health Science Center at San Antonio, San Antonio, Texas; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa A.","family":"Hammond","sequence":"additional","affiliation":[{"name":"1Institute for Drug Development, Cancer Therapy and Research Center and University Health Science Center at San Antonio, San Antonio, Texas; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garry","family":"Schwartz","sequence":"additional","affiliation":[{"name":"2Brooke Army Medical Center, Fort Sam Houston, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Tolcher","sequence":"additional","affiliation":[{"name":"1Institute for Drug Development, Cancer Therapy and Research Center and University Health Science Center at San Antonio, San Antonio, Texas; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amita","family":"Patnaik","sequence":"additional","affiliation":[{"name":"1Institute for Drug Development, Cancer Therapy and Research Center and University Health Science Center at San Antonio, San Antonio, Texas; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Gail","family":"Eckhardt","sequence":"additional","affiliation":[{"name":"1Institute for Drug Development, Cancer Therapy and Research Center and University Health Science Center at San Antonio, San Antonio, Texas; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric K.","family":"Rowinsky","sequence":"additional","affiliation":[{"name":"1Institute for Drug Development, Cancer Therapy and Research Center and University Health Science Center at San Antonio, San Antonio, Texas; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2004,10,8]]},"reference":[{"key":"2022061103422829300_B1","doi-asserted-by":"crossref","unstructured":"Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst\u20082001;93:178-93.","DOI":"10.1093\/jnci\/93.3.178"},{"key":"2022061103422829300_B2","doi-asserted-by":"crossref","unstructured":"Chambers AF, Matrisian LM. Changing views of the role of matrix metallaproteinases in metastasis. J Natl Cancer Inst\u20081997;89:1260-70.","DOI":"10.1093\/jnci\/89.17.1260"},{"key":"2022061103422829300_B3","doi-asserted-by":"crossref","unstructured":"Brown PD, Giavazzi R. Matrix metalloproteinase inhibition: a review of anti-tumor activity. Ann Oncol\u20081995;6:967-74.","DOI":"10.1093\/oxfordjournals.annonc.a059091"},{"key":"2022061103422829300_B4","doi-asserted-by":"crossref","unstructured":"Golub LM, Lee HM, Lehrer G, et al Minocycline reduces gingival collagenolytic activity during diabetes: Preliminary observations and a proposed new mechanism of action. J Periodontal Res\u20081983;18:516-26.","DOI":"10.1111\/j.1600-0765.1983.tb00388.x"},{"key":"2022061103422829300_B5","doi-asserted-by":"crossref","unstructured":"Golub LM, Ramamurthy N, McNamara TF, et al Tetracyclines inhibit tissue collagenase activity: A new mechanism in the treatment of periodontal disease. J Periodontal Res\u20081984;19:651-5.","DOI":"10.1111\/j.1600-0765.1984.tb01334.x"},{"key":"2022061103422829300_B6","doi-asserted-by":"crossref","unstructured":"Golub LM, Goodson JM, Lee HM, Vidal AM, McNamara TF, Ramamurthy NS. Tetracyclines inhibit tissue collagenases: Effects of ingested low-dose and local delivery systems. J Periodontal Res\u20081985;56:93-7.","DOI":"10.1902\/jop.1985.56.11s.93"},{"key":"2022061103422829300_B7","doi-asserted-by":"crossref","unstructured":"Golub LM, Wolff M, Lee HM, et al Further evidence that tetracyclines inhibit collagenase activity in human crevicular fluid and from other mammalian sources. J Periodontal Res\u20081985;20:12-23.","DOI":"10.1111\/j.1600-0765.1985.tb00405.x"},{"key":"2022061103422829300_B8","doi-asserted-by":"crossref","unstructured":"Golub LM, Ramamurthy NS, McNamara TF, Greenwald RA, Rifkin BR. Tetracyclines inhibit connective tissue breakdown: New therapeutic implications for an old family of drugs. Crit Rev Oral Biol Med\u20081991;2:297-321.","DOI":"10.1177\/10454411910020030201"},{"key":"2022061103422829300_B9","doi-asserted-by":"crossref","unstructured":"Hanemaaijer R, Visser H, Koolwijk P, et al Inhibition of MMP synthesis by doxycycline and chemically modified tetracyclines (CMTs) in human endothelial cells. Adv Dent Res\u20081998;12:114-8.","DOI":"10.1177\/08959374980120010301"},{"key":"2022061103422829300_B10","doi-asserted-by":"crossref","unstructured":"Ramamurthy NS, Vernillo AT, Greenwald RA, et al Reactive oxygen species activate and tetracyclines inhibit rat osteoblast collagenase. J Bone Miner Res\u20081993;8:1247-53.","DOI":"10.1002\/jbmr.5650081013"},{"key":"2022061103422829300_B11","doi-asserted-by":"crossref","unstructured":"Smith GNJ, Brandt KD, Hasty KA. Procollagenase is reduced to inactive fragments upon activation in the presence of doxycycline. Ann NY Acad Sci\u20081994;732:436-8.","DOI":"10.1111\/j.1749-6632.1994.tb24778.x"},{"key":"2022061103422829300_B12","doi-asserted-by":"crossref","unstructured":"Smith GNJ, KD, Hasty KA. Activation of recombinant human neutrophil procollagenase in the presence of doxycycline results in fragmentation of the enzyme and loss of enzyme activity. Arthritis Rheum\u20081996;39:235-44.","DOI":"10.1002\/art.1780390209"},{"key":"2022061103422829300_B13","doi-asserted-by":"crossref","unstructured":"Seftor REB, Seftor EA, De Larco JE, et al Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis. Clin Exp Metastasis\u200816\u2008217-25.","DOI":"10.1023\/A:1006588708131"},{"key":"2022061103422829300_B14","doi-asserted-by":"crossref","unstructured":"Myers SA, Wolowacz RG. Tetracycline-based MMP: Inhibitors can prevent fibroblast-mediated collagen gel contraction in vitro. Adv Dent Res\u20081998;12:86-93.","DOI":"10.1177\/08959374980120012701"},{"key":"2022061103422829300_B15","doi-asserted-by":"crossref","unstructured":"Lokeshwar BL. MMP inhibition in prostate cancer. Ann NY Acad Sci\u20081999;878:271-89.","DOI":"10.1111\/j.1749-6632.1999.tb07690.x"},{"key":"2022061103422829300_B16","doi-asserted-by":"crossref","unstructured":"Lokeshwar BL, Selzer MG, Zhu BQ, Block NL, Golub LM. Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog (Col-3) in a metastatic prostate cancer model. Int J Cancer\u20082002;98:297-309.","DOI":"10.1002\/ijc.10168"},{"key":"2022061103422829300_B17","doi-asserted-by":"crossref","unstructured":"Selzer MG, Zhu B, Block NL, Zhu B, Lokeshwar BL. CMT-3, a chemically modified tetracycline, inhibits bony metastases and delays the development of paraplegia in a rat model of prostate cancer. Ann N Y Acad Sci\u20081999;878:678-82.","DOI":"10.1111\/j.1749-6632.1999.tb07760.x"},{"key":"2022061103422829300_B18","doi-asserted-by":"crossref","unstructured":"Seftor REB, Seftor EA, De Larco JE, et al Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis. Clin Exp Metastasis\u20081998;16:217-25.","DOI":"10.1023\/A:1006588708131"},{"key":"2022061103422829300_B19","doi-asserted-by":"crossref","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron\u20081976;16:31-41.","DOI":"10.1159\/000180580"},{"key":"2022061103422829300_B20","doi-asserted-by":"crossref","unstructured":"Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst\u20081997;89:1138-47.","DOI":"10.1093\/jnci\/89.15.1138"},{"key":"2022061103422829300_B21","doi-asserted-by":"crossref","unstructured":"Rudek MA, Figg WD, Dyer V, et al Phase I clinical trial of oral Col-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. J Clin Oncol\u20082001;19:584-92.","DOI":"10.1200\/JCO.2001.19.2.584"},{"key":"2022061103422829300_B22","doi-asserted-by":"crossref","unstructured":"Gough K. Assessment of dose proportionality: Report from the statisticians in the pharmaceutical industry\/pharmacokinetics UK joint working party. Drug Inform J\u20081995;29:1039-48.","DOI":"10.1177\/009286159502900324"},{"key":"2022061103422829300_B23","unstructured":"Noe DA. Noncompartmental pharmacokinetic analysis, in a clinician\u2019s guide to chemotherapy: pharmacokinetics and pharmacodynamics   Grochow LB Ames MM eds.\u20081998515-30.  Williams & Wilkins Baltimore"},{"key":"2022061103422829300_B24","doi-asserted-by":"crossref","unstructured":"Stetler-Stevenson WG. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Investig\u20081999;103:1237-41.","DOI":"10.1172\/JCI6870"},{"key":"2022061103422829300_B25","unstructured":"Khokha R, Denhardt DT. Matrix metalloproteinases and tissue inhibitor of metalloproteinases: A review of their role in tumorigenesis and tissue invasion. Invasion Metastasis\u20081989;9:391-405."},{"key":"2022061103422829300_B26","doi-asserted-by":"crossref","unstructured":"Layton AM, Cunliffe WJ. Phototoxic eruptions due to doxycycline\u2014a dose-related phenomenon. Clin Exp Dermatol\u20081993;18:425-7.","DOI":"10.1111\/j.1365-2230.1993.tb02242.x"},{"key":"2022061103422829300_B27","doi-asserted-by":"crossref","unstructured":"Hasan T, Kochevar IE, McAuliffe DJ, Cooperman BS, Abdulah D. Mechanism of tetracycline phototoxicity. J Investig Dermatol\u20081984;83:179-83.","DOI":"10.1111\/1523-1747.ep12263531"},{"key":"2022061103422829300_B28","doi-asserted-by":"crossref","unstructured":"Miskoski S, Sanchez E, Garavano M, Lopez M, Soltermann AT, Garcia NA. Singlet molecular oxygen-mediated photo-oxidation of tetracyclines: Kinetics, mechanism and microbiological implications. J Photochem Photobiol B\u20081998;43:164-71.","DOI":"10.1016\/S1011-1344(98)00104-3"},{"key":"2022061103422829300_B29","doi-asserted-by":"crossref","unstructured":"Cianfrocca M, Cooley TP, Lee JY, et al Matrix metalloproteinase inhibitor Col-3 in the treatment of aids-related kaposi\u2019s sarcoma: A phase I aids malignancy consortium study. J Clin Oncol\u20082002;20:153-9.","DOI":"10.1200\/JCO.20.1.153"}],"container-title":["Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/10\/19\/6512\/1953731\/zdf01904006512.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/10\/19\/6512\/1953731\/zdf01904006512.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T17:36:07Z","timestamp":1654968967000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article\/10\/19\/6512\/183394\/A-Phase-I-and-Pharmacokinetic-Study-of-Col-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10,1]]},"references-count":29,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2004,10,8]]},"published-print":{"date-parts":[[2004,10,1]]}},"URL":"https:\/\/doi.org\/10.1158\/1078-0432.ccr-04-0804","relation":{},"ISSN":["1078-0432","1557-3265"],"issn-type":[{"value":"1078-0432","type":"print"},{"value":"1557-3265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,10,1]]}}}